Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In the Viewpoint titled “Disease Activity Free Status: A New End Point for a New Era in Multiple Sclerosis Clinical Research?” published online January 6, 2014, and in the March issue of JAMA Neurology (2014;71:269-270. doi:10.1001/jamaneurol.2013.5486), the Table contained a typographical error in the last column. The value for fingolimod in the composite clinical and radiographic disease activity free status should have been 33%. This article has been corrected online.
Incorrect Value in Table. JAMA Neurol. 2014;71(6):803. doi:10.1001/jamaneurol.2014.1265